As a strategy for treatment of cervical cancer, we previously proposed combination therapy with the STAT3 inhibitor S3I-201 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and tested this strategy using SiHa cells [12]. This evidence concerns the gene STAT3 and cervical carcinoma.